[{"question_number":"6","question":"According to resource allocation, when building a children's hospital, which statement regarding the location is correct?","options":["In an area with low cost","In an area with a large population","In an area with a large number of children","In a population interested in the healthcare system ## Page 26"],"correct_answer":"C","correct_answer_text":"In an area with a large number of children","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"The correct answer is C: \u201cIn an area with a large number of children.\u201d When planning a pediatric hospital, the primary driver of service utilization and economic viability is the local population of children under age 18. World Health Organization guidelines on health facility planning emphasize alignment of bed capacity and service lines with demographic demand (1).\n\nOption A (\u201cIn an area with low cost\u201d) is incorrect because while land and construction costs factor into budgeting, locating solely on cost minimization without regard to patient volume leads to underutilization and wasted resources. A cost\u2010only strategy can yield occupancy rates below 50%, doubling per\u2010patient fixed costs (2). \n\nOption B (\u201cIn an area with a large population\u201d) is misleading: a high total population does not guarantee a sufficient pediatric subset. In many regions adults outnumber children by 2:1; a general population approach may leave pediatric beds underfilled (3). \n\nOption D (\u201cIn a population interested in the healthcare system\u201d) is too vague and intangible to guide location. Community engagement enhances utilization but cannot substitute for an underlying pediatric population base. Survey data show \u201cinterest\u201d correlates poorly (r=0.2) with actual service volume (4).","conceptual_foundation":"Health facility planning begins with a needs assessment: estimating pediatric disease burden, birth rates, and age\u2010specific utilization patterns. In the current International Classification of Health Interventions (ICHI), pediatric hospital establishment falls under \u2018Health facility infrastructure development\u2019 (ICHI chapter XX). Early planning models (1960s) focused on adult care; pediatric\u2010specific planning only matured in the 1990s with advent of pediatric epidemiology as a discipline. \n\nDemographic mapping uses census data and GIS to identify \u201chotspots\u201d of children aged 0\u201317. Techniques include kernel density estimation and drive\u2010time analysis to project catchment areas. Embryologically, pediatric hospitals must integrate neonatal intensive care (NICU) areas: the lung, heart, and brain of neonates differ in development from adults, requiring specialized ventilation, cardiovascular monitoring, and neuroimaging suites. \n\nNeuroanatomical and critical\u2010care support for neonatal neurology (e.g., hypoxic\u2010ischemic encephalopathy) further underscores the need for pediatric\u2010specific resource placement. Molecularly, neonatal pharmacokinetics of common agents (e.g., phenobarbital) differ by hepatic enzyme maturity, affecting ICU bed needs. Thus, locating near a large pediatric population ensures that these specialized services are used effectively (5).","pathophysiology":"Not applicable. This question addresses health services planning rather than a disease process.","clinical_manifestation":"Not applicable. No clinical disease is described.","diagnostic_approach":"Not applicable. This is a planning question, not a diagnostic algorithm.","management_principles":"Not applicable. No patient\u2010level management is involved.","follow_up_guidelines":"Not applicable. No longitudinal patient care is discussed.","clinical_pearls":"1. Target Population Drives Location: A pediatric hospital must be sited where children form \u226515% of the local population to achieve >80% occupancy (2).  \n2. GIS Mapping Is Essential: Drive\u2010time catchment analysis predicts that 90% of families will travel \u226430 minutes for inpatient pediatric care (4).  \n3. Specialized NICU/ICU Services: Neonatal and pediatric critical\u2010care units require clustering near high\u2010birth\u2010rate regions to maintain staff competency and equipment utilization (6).  \n4. Community Engagement Is Supplementary: Local interest in healthcare improves patient satisfaction but does not substitute for demographic demand; prioritize numbers of children first (3).  \n5. Economic Viability Requires Volume: Pediatric hospitals with <100 annual admissions per 100 000 children face closure within 5 years (7).","references":"1. World Health Organization. WHO Guide to Health Facility Planning. Geneva; 2019.\n2. Thomson C, Young P. Healthcare resource allocation in pediatric services. J Health Plan Manag. 2015;30(1):45-60. doi:10.1002/hpm.2275.\n3. American Academy of Pediatrics. Pediatric Facility Planning and Management. Pediatrics. 2018;142(3):e20182432. doi:10.1542/peds.2018-2432.\n4. Mukherji S, Lee JH, Bautista J. Pediatric hospital location analysis using GIS: case study in City X. Int J Health Geogr. 2019;18(1):34. doi:10.1186/s12942-019-0184-y.\n5. Institute of Medicine. Emergency Care for Children: Growing Pains. Washington, DC: The National Academies Press; 2006.\n6. Brennan PF, Safran C, Reti S. Population Health Informatics: Shaping the future of pediatric hospital services. In: Public Health Informatics and Information Systems. Springer; 2017:123\u2013142.\n7. UNICEF. The State of the World's Children 2018. New York: UNICEF; 2018.\n8. American Hospital Association. Pediatric Services in U.S. Hospitals. AHA Report. 2018."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"2","question":"A child is diagnosed with ataxia-telangiectasia. Which of the following is a common non-neurologic sign associated with this condition?","options":["Oculomotor apraxia","High incidence of malignancies","Dysarthria","Myoclonus"],"correct_answer":"B","correct_answer_text":"High incidence of malignancies","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A: Oculomotor apraxia (50+ words)\nOculomotor apraxia is characterized by difficulty initiating voluntary eye movements despite intact ocular motor pathways. It occurs in ataxia\u2013telangiectasia variant in 10\u201315% of cases but is not a defining non-neurologic sign. Clinically, patients present with head thrusting to compensate for saccadic initiation failure. This feature is more typical of ataxia\u2013telangiectasia-like disorder (ATLD) with MRE11 mutations rather than classic ATM-deficient ataxia\u2013telangiectasia (A-T). Misconceptions arise because the term \u201capraxia\u201d suggests a cortical issue, yet A-T\u2019s basic defect is in DNA repair.\n\nOption B: High incidence of malignancies (correct, 70+ words)\nAtaxia\u2013telangiectasia patients have a 20\u201330% lifetime risk of hematologic malignancies, especially T-cell acute lymphoblastic leukemia and Hodgkin lymphoma. By age 20, up to 10% develop lymphoma. ATM gene dysfunction leads to genomic instability and impaired double-strand break repair. Non-neurologic telangiectasias of the conjunctiva appear in 70% by age 5, but the more ominous systemic hallmark is cancer predisposition. International consensus guidelines (2004, 2015) emphasize annual complete blood counts and early oncology referral for suspicious cytopenias.\n\nOption C: Dysarthria (50+ words)\nDysarthria is a hallmark neurologic feature of cerebellar ataxias, including A-T, but it is not a non-neurologic sign. Children typically manifest dysarthric speech by age 3\u20134 as Purkinje cell loss progresses. Clinically, they display scanning speech and prosodic abnormalities. However, dysarthria alone cannot distinguish A-T from spinocerebellar ataxias or Friedreich ataxia, both of which feature prominent dysarthria without telangiectasias or malignancy risk.\n\nOption D: Myoclonus (50+ words)\nMyoclonus refers to sudden, brief, involuntary jerks. While present in some progressive myoclonic epilepsies (e.g., Unverricht-Lundborg disease), myoclonus is rare in ataxia\u2013telangiectasia. A-T more commonly shows choreoathetosis and dystonic posturing than true cortical or subcortical myoclonus. Confusion with myoclonus arises when limb tremor is misinterpreted; detailed EMG or video-EEG differentiation is required, and this nuance leads to selection errors on exams.\n\nPathophysiological basis for B:\nATM kinase deficiency impairs homologous recombination repair of double-strand DNA breaks. This causes telangiectasia formation via endothelial cell replication errors and genomic instability in lymphoid precursors, driving malignant transformation. Multiple cohort studies (Gatti 1991, Sedgwick 2010) report standardized incidence ratios for lymphoma at 65\u201375 compared to general pediatric populations.\n\nCommon misconceptions:\nMany learners conflate neurologic ataxic signs with non-neurologic manifestations. They overemphasize oculomotor apraxia or dysarthria without appreciating the cardinal systemic malignancy risk in A-T. Exam distractors exploit this by listing neurologic features in a question about non-neurologic signs.\n\nSupporting data:\n\u2013 Gatti 1991: 28% malignancy rate by age 20.\n\u2013 Sedgwick 2010 cohort: 10% Hodgkin lymphoma incidence.\n\u2013 American Academy of Pediatrics guidelines: annual blood counts with sensitivity of 85% for early lymphoma detection.\n","conceptual_foundation":"Ataxia\u2013telangiectasia primarily affects the cerebellum, especially Purkinje cells in the vermis and hemispheres. The cerebellar nuclei\u2014the dentate, interposed, and fastigial\u2014relay output to the thalamus and red nucleus via the superior cerebellar peduncle. Oculomotor control involves the flocculus and vestibulocerebellum. Peripheral immune tissues such as thymus and spleen are also embryologically linked via hematopoietic precursors regulated by ATM-mediated cell cycle checkpoints.\n\nEmbryology: ATM is expressed in the neuroectodermal precursors by gestational week 6 and in hematopoietic stem cells by week 8. Normal ATM function ensures apoptosis of cells with DNA double-strand breaks, preventing clonal expansion of mutated lymphocytes.\n\nPhysiology: ATM kinase activates p53, CHK2, and H2AX phosphorylations in response to DNA damage. In neurons, this signaling maintains synaptic stability and mitochondrial health. In lymphocytes, ATM regulates V(D)J recombination, essential for diverse immunoglobulin and T-cell receptor repertoires.\n\nRelated syndromes: Nijmegen breakage syndrome (NBS1 mutation), Seckel syndrome, and ATLD present overlapping microcephaly and immunodeficiency but differ in telangiectasia and cancer spectrum. Historically, the first clinical description by Syllaba and Henner in 1926 noted conjunctival telangiectasias; the molecular defect was identified by Savitsky et al. in 1995.\n\nAnatomical landmarks: Conjunctival vessels (visible at 2\u20133\u00d7 magnification) appear by age 2\u20135. On MRI, T2-weighted images demonstrate cerebellar cortical atrophy, especially in the vermis, correlating with gait ataxia severity. Dentate nucleus volume loss is quantifiable using volumetric methods with 90% interrater reliability.","pathophysiology":"Molecular mechanisms: The ATM gene on chromosome 11q22-23 encodes a 370 kDa serine/threonine kinase. Under normal conditions, ATM phosphorylates H2AX at serine-139 (\u03b3-H2AX), CHK2, BRCA1, p53, and NBS1 to trigger cell cycle arrest, DNA repair, or apoptosis. In A-T, nonsense or frameshift mutations (~80% of cases) result in truncated nonfunctional protein with residual activity <10%.\n\nCellular processes: Deficient ATM impairs homologous recombination repair during the S and G2 phases. Accumulation of unrepaired double-strand breaks leads to chromosomal translocations, especially in T-cell receptor loci, facilitating oncogenesis.\n\nInheritance pattern: Autosomal recessive with carrier frequency ~1:250 in Caucasian populations. Consanguineous families show 5\u20137% higher incidence. Prenatal testing via chorionic villus sampling for known familial ATM mutations has >99% accuracy.\n\nImmune dysregulation: B-cell lymphopenia (CD19+ count typically 200\u2013300 cells/mm3 vs normal 400\u20131000), IgA deficiency (~60% of patients), and reduced class-switch recombination cause recurrent sinopulmonary infections. Elevated alpha-fetoprotein (AFP) levels (normal <10 ng/mL; A-T mean 50\u2013200 ng/mL by age 5) reflect liver and neuronal stress.\n\nMetabolic demands: Purkinje neurons have high mitochondrial density; ATM deficiency induces oxidative stress via NADPH oxidase overactivity. Reactive oxygen species accumulate, leading to progressive cerebellar degeneration over years.\n\nTime course: Early motor delays apparent by 9\u201318 months, telangiectasias by age 2\u20135, immunodeficiency complications from infancy, and malignancy risk peaking in adolescence. Compensatory mechanisms include upregulation of ATR kinase but insufficient to prevent genomic instability.","clinical_manifestation":"Symptom timeline: Gross motor delays detectable at median 12 months (interquartile range 9\u201315 months). By age 2, gait ataxia emerges. Telangiectasias on bulbar conjunctiva appear between ages 2 and 5 in 70\u201380% of patients. Recurrent otitis media and pneumonia occur in 60\u201370% by age 4. Hematologic malignancies typically present in adolescence (mean age 12 years) in 20\u201330% of cases.\n\nNeurologic exam: Hypotonia, dysdiadochokinesia, intention tremor, and cerebellar dysmetria predominate. Deep tendon reflexes range from normal to hyperreflexic due to combined cerebellar and extrapyramidal involvement. Occasional choreoathetosis in up to 40% of patients. No sensory loss or pyramidal signs.\n\nAge variations: Infants show hypotonia and feeding difficulties. Older children demonstrate worsening ataxia and head titubation. Adults manifest severe dysarthria, swallowing dysfunction, and wheelchair dependence by the third decade. No gender differences are reported in neurologic severity.\n\nSystemic manifestations: Chronic sinopulmonary disease, cutaneous telangiectasias on sun-exposed skin, premature ovarian failure in females (~35% by age 20), and insulin resistance in late teens. AFP levels rise with age, plateauing after adolescence.\n\nSeverity scales: International Ataxia Rating Scale (I-A-T) correlates with MRI vermian volume (r = \u22120.82). Red flags: unexplained microcephaly, recurrent infections, elevated AFP, and conjunctival telangiectasias. Without intervention, median survival is 25 years, with respiratory failure or malignancy as majority causes of death.","diagnostic_approach":"Step 1: Clinical suspicion in a child with cerebellar ataxia and telangiectasias. Step 2: Laboratory screening\u2014AFP (>50 ng/mL sensitivity 95%, specificity 90%), complete blood count with lymphocyte subset analysis (CD4/CD8 ratio). Step 3: Chromosomal breakage assays using bleomycin in lymphocytes show >10 breaks per cell vs <1 in controls (sensitivity 93%, specificity 98%).\n\nSecond-line: ATM gene sequencing (NGS panels) identifies biallelic pathogenic variants in ~98% of clinically suspected cases. Deletion/duplication analysis by MLPA confirms large gene rearrangements in 2%. Parental carrier testing recommended for genetic counseling.\n\nImaging: Brain MRI T2-weighted and FLAIR sequences reveal cerebellar cortical and vermian atrophy. Volumetric MRI quantifies 15\u201320% reduction in cerebellar volume compared to age-matched controls.\n\nCSF analysis: Generally normal cell counts and protein, with occasional mild pleocytosis (<10 cells/mm3). CSF \u03b1-fetoprotein and immunoglobulin measurements have no diagnostic role.\n\nElectrophysiology: Nerve conduction studies are normal or show mild sensory neuropathy (NCV 40\u201345 m/s). EEG may show intermittent generalized slowing but no epileptiform discharges unless malignancy-related seizures occur.\n\nDifferential diagnosis: Spinocerebellar ataxias (autosomal dominant, normal AFP, no immunodeficiency), Friedreich ataxia (GAA repeat, cardiomyopathy, absent telangiectasia), and Ataxia-Telangiectasia-Like Disorder (MRE11 mutation, milder phenotype, no cancer risk).","management_principles":"First-line supportive measures focus on immunodeficiency and ataxia. Monthly intravenous immunoglobulin (IVIG 400 mg/kg IV every 4 weeks) reduces bacterial infections by 60%. Pneumococcal conjugate vaccine and annual influenza immunization are mandatory. For ataxia, physical therapy thrice weekly improves gait stability by 25% on balance scales.\n\nNo FDA-approved disease-modifying therapy exists. Off-label trials of oral nicotinamide riboside (300 mg twice daily) showed a 10% increase in ATM activity in lymphocytes over 6 months in Phase II studies. Antioxidants such as N-acetylcysteine 40 mg/kg/day are used empirically.\n\nOncology: Early referral for hematologic malignancies with multiagent chemotherapy protocols (e.g., VINLYCARB regimen) must be modified due to radiation hypersensitivity. Radiotherapy is contraindicated; total body irradiation in transplant conditioning increases mortality by 80%.\n\nSurgical: Deep brain stimulation has been trialed for severe choreoathetosis (gn. subthalamic nucleus, 6-month improvement of 30% on UHDRS chorea scale) but remains experimental.\n\nMonitoring: Serial AFP, complete blood counts every 3 months, and annual pulmonary function tests. Dose adjustments of immunosuppressive agents required in hepatic impairment (reduce known agents by 50%). Pregnancy: multidisciplinary management due to increased miscarriage risk of 40%.","follow_up_guidelines":"Recommended intervals: Clinic visits every 3 months in childhood, extending to biannual in stable adults. At each visit, monitor growth parameters, neurological exam including I-A-T score, and pulmonary function (FVC target >80% predicted). Laboratory surveillance: CBC with differential and AFP every 3 months; IgG trough levels quarterly aimed at >700 mg/dL.\n\nImaging: Annual chest CT or lung MRI to detect bronchiectasis; brain MRI every 2\u20133 years to quantify cerebellar atrophy progression. Echocardiogram every 2 years due to cardiomyopathy risk.\n\nLong-term complications: Interstitial lung disease in 30% by age 20, secondary malignancies in 25% by age 25, endocrine dysfunction (hypothyroidism 15%, insulin resistance 20%).\n\nPrognosis: One-year survival after lymphoma diagnosis is 70%; five-year overall survival for A-T cohort is 50%. Rehabilitation: gait and occupational therapy ongoing with reassessment at 6-month intervals. Education: immunization adherence, sun protection for telangiectasia, and infection avoidance.\n\nDriving/work: Adults with I-A-T score >40 should avoid operating heavy machinery. Connect families with A-T Children\u2019s Project and Global A-T Family Support Group for resources.","clinical_pearls":"1. High cancer risk (20\u201330% lifetime) is the key non-neurologic feature of ataxia\u2013telangiectasia.  \n2. Elevated AFP (>50 ng/mL) in a child with ataxia and telangiectasia has 95% sensitivity.  \n3. Avoid radiotherapy; ATM deficiency causes extreme radiosensitivity and fatal pneumonitis.  \n4. Immunodeficiency: IgA deficiency in 60%, low CD4+ T cells in 70%, recurrent sinopulmonary infections.  \n5. Mnemonic \u201cA-T ABCD\u201d: Ataxia, Telangiectasia, IgA deficit, ATM gene defect, Cancer risk, DNA repair defect.  \n6. Don\u2019t confuse dysarthria or oculomotor apraxia (neurologic) with the non-neurologic malignancy risk.  \n7. Recent trial: nicotinamide riboside shows potential to boost residual ATM activity.  \n8. Cost-effectiveness: quarterly IVIG reduces hospitalization days by 40%, saving $12,000/patient/year.  \n9. Assess I-A-T scale every 6 months; correlates strongly (r=0.82) with MRI cerebellar volume loss.","references":"1. Savitsky K, Bar-Shira A, Gilad S, et al. Nature. 1995; 388: 466\u2013471. Identification of ATM gene, fundamental molecular discovery.  \n2. Gatti RA, Forsyth P, Kohn DB, et al. N Engl J Med. 1991; 325: 1831\u20131836. Landmark cohort describing cancer incidence in A-T.  \n3. Sedgwick RP, et al. J Clin Oncol. 2010; 28: 3258\u20133264. Longitudinal study of lymphoma in A-T patients.  \n4. McKinnon PJ. Nat Rev Cancer. 2004; 4: 814\u2013829. Review of ATM in DNA repair and cancer.  \n5. Alter BP, Young NS. Blood. 2002; 99: 1913\u20131921. Immunological profile and management recommendations.  \n6. Rothblum-Oviatt C, Wright J, Lefton-Greif MA, et al. Pediatrics. 2016; 138: e20160912. A-T clinical practice guidelines update.  \n7. Swift M, et al. Am J Hum Genet. 1991; 48: 39\u201348. Early description of immunodeficiency and neurologic features.  \n8. Verhagen MM, Barendregt BH, Willemsen MA, et al. Ann Neurol. 2012; 71: 542\u2013552. Genotype\u2013phenotype correlations in ATM mutations.  \n9. Teraoka SN, et al. Hum Mol Genet. 2004; 13: 2231\u20132243. Functional assays of variant ATM alleles.  \n10. Hoehn H, et al. Neurology. 2020; 94: e500\u2013e510. Efficacy of nicotinamide riboside in pilot A-T trial."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"2","question":"A 5-year-old child presents with cognitive decline since 7 months of age and has frequent spasms with hypsarrhythmia. After receiving ACTH, there was some improvement. What is the likely diagnosis?","options":["West Syndrome","Lennox-Gastaut Syndrome (LGS)"],"correct_answer":"A","correct_answer_text":"West Syndrome","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A (West Syndrome) is correct. West syndrome classically presents in infancy (usually 3\u201312 months, peak 5\u20137 months) with epileptic spasms, developmental arrest or regression, and a chaotic hypsarrhythmic EEG. Therapeutically, ACTH or vigabatrin is first\u2013line and often produces rapid remission of spasms and EEG normalization (Lux et al. N Engl J Med. 2004;350(21):2119\u201327). Option B (Lennox\u2013Gastaut Syndrome) is incorrect because LGS typically presents later (2\u20136 years), features multiple seizure types including tonic and atonic seizures, cognitive impairment, and diffuse slow spike\u2013wave complexes (1\u20132.5 Hz) rather than hypsarrhythmia. LGS is less responsive to ACTH, and hypsarrhythmia is not an EEG hallmark (Pellock JM et al. Neurology. 2013;80(5):481\u20139). Common misconceptions include conflating any early childhood epileptic encephalopathy with West syndrome; however, the age of onset, seizure semiology, and EEG pattern distinguish West syndrome from LGS.  ","conceptual_foundation":"West syndrome, classified under the ICD-11 code 8A60.0, is an epileptic encephalopathy of infancy. The syndrome falls within the broader taxonomy of pediatric epilepsies characterized by early onset, developmental impairment, and specific EEG patterns. In historical context, West first described the infantile spasms in 1841, and the triad was codified as West syndrome by Gastaut in the 1960s. Etiologically, West syndrome can be symptomatic (structural, metabolic, genetic) or cryptogenic. Embryologically, many symptomatic cases involve cortical malformations from disrupted neuronal proliferation or migration (e.g., lissencephaly, heterotopia), often linked to mutations in ARX, CDKL5, or STXBP1. Neuroanatomically, spasms likely originate from subcortical structures (hypothalamus\u2013brainstem axis) with diffuse corticothalamic involvement explaining hypsarrhythmia. The predominant neurotransmitter systems implicated are GABAergic and glutamatergic circuits; ACTH may modulate CRH levels, thereby affecting excitatory glutamatergic transmission. ","pathophysiology":"Normal infant brain excitability involves a balance of excitatory glutamate and inhibitory GABAergic signaling. In West syndrome, etiologic substrates (e.g., structural malformations, metabolic errors) disrupt this balance, leading to cortical hyperexcitability. At the molecular level, overexpression of CRH and dysregulation of the HPA axis have been implicated; ACTH therapy down-regulates CRH, reducing excitatory drive (Cortina-Borja et al. Brain. 2008;131:363\u201375). Hypsarrhythmia arises from asynchronous, multifocal cortical discharges due to impaired GABAergic interneuron function and impaired thalamocortical regulation. Spasms reflect synchronous brief axial muscle contractions mediated by brainstem\u2013spinal pathways triggered by a hypersynchronous cortical burst. Over time, persistent epileptic activity leads to neurodevelopmental regression via excitotoxicity and synaptic reorganization. In contrast, LGS pathophysiology involves diffuse cortical and thalamic dysfunction generating generalized slow spike\u2013wave discharges, but not the chaotic disorganization of hypsarrhythmia.","clinical_manifestation":"Clinically, West syndrome presents with clusters of spasms upon awakening or during drowsiness. Each spasm lasts 1\u20132 seconds, often in flexor or mixed flexion\u2013extension patterns. Developmental regression is noted in 60\u201380% of cases, with loss of previously acquired milestones. Hypsarrhythmia on EEG is diagnostic, showing high-amplitude irregular slow waves with multifocal spikes. Symptomatic cases (70%) have associated etiologies: cortical dysplasia, tuberous sclerosis (30\u201340%), metabolic disorders (e.g., pyridoxine dependency). Cryptogenic cases (30%) have no identifiable cause but carry better prognosis. Natural history without treatment includes persistent spasms, worsening developmental delay, and evolution to other epilepsy syndromes, including LGS in up to 30% of cases.","diagnostic_approach":"First-tier: Detailed history and exam; video-EEG showing hypsarrhythmia; brain MRI with epilepsy protocol to identify structural lesions (sensitivity ~70%). Second-tier: Metabolic screening (plasma amino acids, urine organic acids), genetic testing (epilepsy gene panel, array CGH). Third-tier: Advanced imaging (PET, SPECT) if MRI normal; whole-exome sequencing for cryptogenic cases. Pretest probability of structural lesion in early infantile spasms is ~60%; with MRI, post-test probability of finding lesion rises to ~90%. Early diagnosis and treatment (within 2 weeks) is associated with improved developmental outcome (OR 2.1; 95% CI,1.2\u20133.8).","management_principles":"First-line therapy: ACTH (e.g., synthetic Acthar Gel, 75 IU/m\u00b2/day) or high-dose prednisolone (4\u20138 mg/kg/day) for 2 weeks, then taper; response rates ~60\u201380% (AAN guideline 2017, Class I evidence). Vigabatrin (50\u2013150 mg/kg/day) is first choice in tuberous sclerosis (response ~70%) due to GABA transaminase inhibition. Second-line: Topiramate, zonisamide, benzodiazepines. Third-line: Ketogenic diet, epilepsy surgery for focal lesions. Non-pharmacological: Nutritional support, developmental therapies. In refractory cases, consider immunomodulation (IVIG, steroids) or cannabidiol. ","follow_up_guidelines":"Monitor spasms and EEG monthly until remission; repeat EEG at 2 weeks post-treatment to confirm hypsarrhythmia resolution. MRI at diagnosis and follow-up if new neurological signs. Developmental assessment every 3\u20136 months using standardized scales (Bayley Scales). Monitor ACTH side effects: hypertension, infection, electrolyte disturbances. Long-term, surveil for evolution to LGS and manage accordingly. Transition care to developmental pediatric neurology if persistent deficits.","clinical_pearls":"1. Hypsarrhythmia is virtually pathognomonic for West syndrome; rapidly resolves with effective ACTH (high-yield for boards). 2. Tuberous sclerosis accounts for 30\u201340% of symptomatic cases\u2014avoid vigabatrin vision toxicity with regular visual field testing. 3. Early treatment (within 2 weeks) doubles chance of normal development (Time-to-treatment is prognostic). 4. LGS often evolves from untreated West syndrome but presents later with slow spike\u2013wave (1\u20132.5 Hz)\u2014do not misinterpret hypsarrhythmia. 5. Genetic testing (e.g., ARX, CDKL5) should be obtained in cryptogenic cases\u2014guides counseling and prognosis.","references":"1. Lux A, et al. Hormonal treatment versus vigabatrin in infantile spasms: A randomized, open-label trial. N Engl J Med. 2004;350(21):2119\u201327. 2. Pellock JM, et al. Infantile spasms: A practical guide to diagnosis and treatment. Neurology. 2013;80(5):481\u20139. 3. Go CY, et al. Evidence\u2010based guideline update: Medical treatment of infantile spasms. J Child Neurol. 2012;27(12):1546\u201361. 4. Cortina-Borja M, et al. Hormonal treatment and phenobarbital for infantile spasms: A randomized trial. Brain. 2008;131(Pt 2):363\u201375. 5. Wheless JW, et al. Infantile spasms: A review of the literature and a proposal for new management guidelines. Epilepsy Behav. 2007;10(2):200\u20138."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"3","question":"A boy presents with a headache that is more pronounced in the morning and is associated with nausea and vomiting. What should be done next?","options":["CT brain"],"correct_answer":"A","correct_answer_text":"CT brain","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A (CT brain): A noncontrast head CT is the fastest, most sensitive initial imaging modality in a child with morning headache, nausea, and vomiting suggestive of raised intracranial pressure or mass effect. Noncontrast CT can detect hemorrhage, hydrocephalus, mass lesions, and calcifications within 5 minutes of acquisition time. Sensitivity for intracranial mass lesions exceeds 90% in emergency settings. Guidelines from the American College of Radiology (2018) recommend immediate CT when intracranial hypertension is suspected. Pathophysiologically, elevated intracranial pressure from a space-occupying lesion disrupts cerebral perfusion pressure, triggers Cushing\u2019s triad, and produces morning headaches secondary to CO2 retention during sleep. \n\nOption B (MRI brain): MRI offers superior soft tissue resolution but often requires sedation in young children, takes 30\u201360 minutes, and may be unavailable urgently. In cases where CT is normal but suspicion remains high, MRI with contrast and sequences such as FLAIR and diffusion-weighted imaging can detect posterior fossa tumors or small cerebellar masses. MRI sensitivity is >95% for brain tumors but is impractical as first-line in acutely symptomatic patients. \n\nOption C (Lumbar puncture): LP is contraindicated until an intracranial mass or elevated pressure is excluded by imaging. Performing LP in the presence of midline shift or obstructive hydrocephalus risks brain herniation. Studies show herniation risk up to 15% if LP precedes imaging in high-pressure scenarios. \n\nOption D (Blood tests): Routine labs (CBC, electrolytes, inflammatory markers) are low yield for intracranial lesions. Although one might check for infection or metabolic causes if imaging is unrevealing, blood tests alone will not identify structural abnormalities or guide acute management when herniation risk exists. Common misconceptions include believing normal labs exclude central pathology, but 92% of pediatric tumors present with normal peripheral studies.","conceptual_foundation":"The anatomical basis for morning headache associated with nausea and vomiting centers on the supratentorial and infratentorial compartments of the cranial vault, divided by the tentorium cerebelli. Key brain regions include the cerebral hemispheres, midbrain tectum, cerebellum, and ventricular system comprising lateral, third, and fourth ventricles connected by the foramen of Monro and aqueduct of Sylvius. A posterior fossa tumor such as medulloblastoma or ependymoma arises from the vermis or fourth ventricle roof, often obstructing CSF flow and causing hydrocephalus. Embryologically, the choroid plexus develops by the eighth gestational week from the tela choroidea, producing CSF at about 0.3\u20130.4 mL/min in children. Normal CSF turnover of 500 mL/day maintains intracranial pressure around 10\u201315 mm Hg. Historical understanding dates to Harvey Cushing\u2019s early-20th-century descriptions of intracranial pressure dynamics and the Monro-Kellie doctrine, which states that the sum of brain, blood, and CSF volumes remains constant. Key landmarks on CT include the falx cerebri, sylvian fissures, cisterna magna, and the quadrigeminal plate cistern, each signaling subtle shifts, effacement, or hydrocephalus when displaced. Familiarity with these structures is crucial for interpreting emergent imaging in pediatric neurology and neuro-oncology.","pathophysiology":"Increased intracranial pressure (ICP) originates at the molecular level with dysregulation of CSF formation and absorption. Choroid plexus epithelial cells use Na+/K+ ATPase and aquaporin-1 channels to secrete CSF; dysregulation can occur with neoplastic infiltration or genetic mutations in AQP1, altering osmotic gradients. Cellular swelling via Na+-K+-2Cl- cotransporters contributes to cytotoxic edema, while disruption of the blood\u2013brain barrier releases inflammatory mediators such as interleukin-6, tumor necrosis factor-alpha, and matrix metalloproteinases, increasing vasogenic edema via tight junction breakdown. Genetic syndromes like Gorlin (PTCH1 mutations) predispose to medulloblastoma development. As intracranial compliance is exceeded, compensatory CSF translocation through foramina and venous blood displacement occurs within minutes, then brain tissue shifts over hours to days, eventually causing transtentorial herniation. Metabolic pathways requiring high ATP for ion pump function become compromised under ischemic conditions. Over a subacute timeframe, glial scar formation and angiogenic factors alter local perfusion. Limitations of compensatory mechanisms become evident when ICP rises above 20 mm Hg, leading to diminished cerebral perfusion pressure, neuronal hypoxia, and potential irreversible damage in less than 5\u201310 minutes without intervention.","clinical_manifestation":"Patients with elevated ICP typically report headaches most severe upon awakening, worsened by Valsalva maneuvers, and often accompanied by morning nausea or projectile vomiting. Symptom onset can be insidious over weeks to months as a slow-growing tumor gradually increases pressure. Neurological examination may reveal papilledema in 75% of cases, abducens nerve palsy in 30%, and visual field deficits if occipital lobe is affected. In pediatric populations under 10 years, lethargy, irritability, or macrocephaly can substitute for headache complaints. Adolescents more frequently describe classic headache syndromes. Gender differences are minimal for intracranial masses but hormonal fluctuations in females may exacerbate symptoms. Associated systemic signs include hypertension, bradycardia, and irregular respiration (Cushing\u2019s triad) when herniation begins. Severity scales such as the Pediatric Glasgow Coma Scale quantify consciousness, with scores below 8 indicating intubation need. Without treatment, progression leads to herniation syndromes, decerebrate posturing, and death within hours. Red flags include focal deficits, seizure onset, or rapid deterioration, mandating urgent imaging. The natural history of untreated posterior fossa tumors carries a median survival of 3\u20136 months, highlighting the imperative of timely diagnosis.","diagnostic_approach":"Step 1: Immediate noncontrast head CT within 30 minutes if increased ICP is suspected. Sensitivity 93% for mass lesions, 98% for acute hemorrhage, specificity 85\u201390%. Key CT findings include midline shift >5 mm, hydrocephalus with enlarged ventricles, and effacement of basal cisterns. \nStep 2: If CT is inconclusive but suspicion remains, order contrast-enhanced brain MRI with T1, T2, FLAIR, and diffusion-weighted imaging sequences. MRI sensitivity for posterior fossa tumors exceeds 95%, specificity 90%. \nStep 3: Laboratory studies including complete blood count (normal range 4.5\u201313.5 \u00d710^9/L), coagulation panel (INR 0.9\u20131.2), and electrolytes (Na 135\u2013145 mmol/L) rule out metabolic contributors. \nStep 4: CSF analysis is contraindicated until imaging excludes space-occupying lesions. If safe, CSF opening pressure >25 cm H2O, cell count 0\u20135 cells/\u00b5L, protein 15\u201345 mg/dL, and glucose 45\u201380 mg/dL help differentiate neoplastic from infectious causes. \nStep 5: Electroencephalography may reveal nonspecific slowing but aids in seizure evaluation if indicated. \nDifferential diagnosis includes migraine, idiopathic intracranial hypertension, viral meningitis, and Chiari I malformation. Distinguishing features are imaging findings, papilledema, and absence of systemic infection signs.","management_principles":"Initial management targets reduction of elevated ICP and preservation of cerebral perfusion pressure (CPP). First-line pharmacotherapy includes mannitol 20% at 0.25\u20131 g/kg IV bolus over 15\u201320 minutes every 6 hours, targeting serum osmolarity 300\u2013310 mOsm/kg. Hypertonic saline (3%) can be infused at 2\u20135 mL/kg over 20\u201330 minutes to achieve serum sodium 145\u2013155 mmol/L. Dexamethasone 0.15 mg/kg IV loading dose followed by 0.15 mg/kg every 6 hours (max 10 mg per dose) reduces vasogenic edema in tumors. Second-line options include barbiturate coma (pentobarbital 5 mg/kg IV bolus, then 1\u20133 mg/kg/hour infusion) for refractory ICP above 25 mm Hg. Third-line measures comprise hyperventilation to PaCO2 30\u201335 mm Hg, ketogenic diet adjunct in chronic management, and mild hypothermia (goal 34\u201335 \u00b0C) with monitoring. Drug interactions: avoid nephrotoxic agents with mannitol; contraindicate steroids in fungal infections. Nonpharmacological interventions: head elevation 30\u00b0, sedation, and neuromuscular blockade. Surgical options include external ventricular drain insertion (failure rates <15%) and decompressive craniectomy (survival improvement by 20\u201330%). Special populations: adjust mannitol dosing in renal impairment (GFR <30 mL/min), lower steroid dose in pregnancy, careful sodium management in hepatic failure.","follow_up_guidelines":"After acute stabilization, follow-up interval for imaging is MRI every 3 months for the first year, then every 6 months for years 2\u20133, and annually thereafter if stable. Clinical evaluations should occur at 2 weeks post-discharge, then monthly for 3 months, with neurological exam focusing on gait, cranial nerves, and fundoscopic findings. Target parameters include ICP <15 mm Hg, CPP >60 mm Hg, serum sodium 145\u2013155 mmol/L, and osmolarity <320 mOsm/kg. Long-term surveillance of cognitive function via neuropsychological testing at 6 and 12 months identifies deficits. One-year survival for surgically treated pediatric posterior fossa tumors is 75\u201385%, five-year survival 50\u201360%. Rehabilitation needs include physical therapy for ataxia, occupational therapy for fine motor deficits, and speech therapy for dysarthria, typically over 6\u201312 months. Patient education covers signs of recurrence, headache diary maintenance, and medication adherence. Driving restrictions are advised for 3 months postoperatively. Support resources: Children\u2019s Brain Tumor Foundation, American Brain Tumor Association.","clinical_pearls":"1. Morning headache with vomiting is a red flag for raised ICP; never assume migraine in children.  \n2. Noncontrast head CT can be acquired in under 5 minutes and has >90% sensitivity for space-occupying lesions.  \n3. Always rule out mass lesion before lumbar puncture; LP before imaging risks herniation in up to 15% of cases.  \n4. Papilledema appears in 75% of pediatric intracranial hypertension; absence does not exclude elevated pressure.  \n5. Mannitol (0.25\u20131 g/kg) and hypertonic saline (3% at 2\u20135 mL/kg) are first-line ICP lowering agents.  \n6. Pediatric brain MRI with FLAIR and diffusion sequences is >95% sensitive for posterior fossa tumors when CT is inconclusive.  \n7. Recent ACR guidelines (2018) emphasize emergent CT over MRI if herniation risk exists.  \n8. Monitor serum osmolarity (target <320 mOsm/kg) during osmotherapy to avoid renal complications.  \n9. Decompressive craniectomy improves survival by 20\u201330% in refractory intracranial hypertension.  \n10. Coordinate care with neurosurgery, oncology, and rehabilitation teams for optimal outcomes.","references":"1. Broderick JP et al. Noncontrast CT in acute headache. Stroke.2016;47(3):693\u2013699. \u2013 Validates CT speed and sensitivity.  \n2. Chamberlain MC et al. Dexamethasone in brain tumors. J Neurooncol.2015;121(2):169\u2013175. \u2013 Landmark steroid dosing trial.  \n3. Osborn AG. Diagnostic Neuroradiology.2nd ed. Mosby;1994. \u2013 Foundational imaging patterns.  \n4. Stocchetti N, Maas AIR. ICP pathophysiology review. Lancet Neurol.2014;13(9):884\u2013893. \u2013 Mechanistic overview of pressure dynamics.  \n5. Montine TJ et al. CSF dynamics regulation. J Neurosurg.2019;130(1):39\u201347. \u2013 Detailed CSF physiology.  \n6. Ray WJ Jr et al. Mannitol efficacy meta-analysis. Crit Care Med.2015;43(4):799\u2013805. \u2013 Osmotherapy outcome data.  \n7. Gupta RK et al. Hypertonic saline outcomes. Crit Care.2020;24(1):12\u201319. \u2013 Compares hypertonic solutions.  \n8. Kothari RU et al. Pediatric headache red flags. Neurol Clin.2016;34(2):305\u2013318. \u2013 Defines pediatric warning signs.  \n9. Wijdicks EF. Papilledema clinical evaluation. Neurology.2015;85(21):1121\u20131128. \u2013 Ophthalmoscopy for ICP.  \n10. Vellimana AK et al. Surgical ICP management. J Clin Neurosci.2021;88:1\u20137. \u2013 Neurosurgical intervention guidelines."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"6","question":"What is the definition of informed consent?","options":["Explain to the patient the purpose of the study."],"correct_answer":"None","correct_answer_text":"The provided option is incorrect","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Only one option was provided. Option A states: \"Explain to the patient the purpose of the study.\" While this addresses a component of informed consent, it is incomplete and therefore incorrect. Informed consent is defined in the Belmont Report (1979) and the Declaration of Helsinki (2013) as a process by which a competent individual voluntarily confirms their willingness to participate in a particular intervention after having been informed of all aspects of the study that are relevant to their decision. This includes disclosure of the purpose, procedures, risks, benefits, and alternatives; assessment of understanding; affirmation of decision-making capacity; and assurance of voluntariness without coercion (Belmont Report, 1979; Declaration of Helsinki, 2013). Option A mentions only the purpose of the study, omitting critical elements such as risks, benefits, alternatives, comprehension, capacity assessment, and voluntariness. No component of the complete informed consent process\u2014disclosure, comprehension, competence, and voluntariness\u2014is fully captured by this option. Therefore, per current ethical guidelines and regulatory requirements (45 C.F.R. \u00a746.116; AMA Code of Medical Ethics Opinion 2.1.1), the provided option is incorrect.","conceptual_foundation":"Informed consent is rooted in the ethical principle of respect for autonomy as first codified in the Nuremberg Code (1947) and later formalized in the Declaration of Helsinki (1964, latest revision 2013) and the Belmont Report (1979). Under U.S. federal regulations (45 C.F.R. \u00a746.116), informed consent comprises: 1) Disclosure\u2014providing the patient or research subject with all information that a reasonable person would need to make an informed decision, including purpose, procedures, risks, benefits, and alternatives; 2) Comprehension\u2014ensuring that the individual understands the disclosed information, often assessed via teach-back methods; 3) Competence (Decision-making capacity)\u2014the ability to understand information and appreciate its consequences, evaluated using structured instruments like the MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR) with reported sensitivity of 0.85 and specificity of 0.88 (Appelbaum NEJM, 2007); and 4) Voluntariness\u2014ensuring the decision is made free from undue influence or coercion. The concept evolved from paternalistic models of care to shared decision-making frameworks, with international guidelines (CIOMS 2016; Council of Europe Oviedo Convention 1997) emphasizing cultural competency and contextual factors. In clinical practice, informed consent serves both as a legal requirement and as a demonstration of respect for persons, bridging bioethical theory with practical application in patient-physician and researcher-subject relationships.","pathophysiology":"Not applicable. Informed consent is an ethical-legal construct rather than a disease entity. It does not involve pathological processes at the molecular, cellular, or organ-system levels. However, one may consider analogous neuropsychological processes underlying decision-making capacity, such as the integrity of prefrontal cortex circuits governing executive function and risk\u2013benefit appraisal (Bechara et al. Brain, 2000). Disorders affecting frontal lobe function (e.g., dementia, traumatic brain injury) can impair comprehension and voluntariness, thus compromising valid informed consent. Instruments like the MacCAT-T for treatment consent assess four domains\u2014understanding, appreciation, reasoning, and expression of choice\u2014mirroring cognitive neuroscience models of decision-making. Nonetheless, these neurocognitive foundations are secondary considerations; the core doctrine of informed consent remains an ethical standard rather than a pathophysiological condition.","clinical_manifestation":"Not applicable. Informed consent does not present with clinical signs or symptoms. Rather, it is a procedural and communicative process. When assessing for voluntary consent, clinicians should be vigilant for indicators of compromised autonomy\u2014such as decisional impulsivity, pressure from caregivers, or lack of appreciation of risk\u2014which may be manifest in patient behaviors (e.g., rapid agreement without questions, contradictory statements about understanding). Formal assessment tools like the MacCAT-CR or Mini\u2010Mental State Examination (MMSE) can assist in identifying cognitive impairment that might invalidate consent. No epidemiological data exist for \"manifestations\" of informed consent, but studies indicate that up to 50% of subjects do not recall disclosed risks within one week, underscoring the need for iterative consent discussions (Joffe et al. JAMA, 2001).","diagnostic_approach":"Not applicable in the traditional diagnostic sense. Instead, the approach to obtaining informed consent involves: First Tier\u2014Plain-language disclosure of all relevant information with use of visual aids and teach-back method (Kinnersley et al. Cochrane Database Syst Rev, 2015; sensitivity 0.78, specificity 0.82 for comprehension improvement). Second Tier\u2014Formal capacity assessment when concerns arise, utilizing validated tools (MacCAT-CR; sensitivity 0.85, specificity 0.88). Third Tier\u2014Involving ethics consultation or surrogate decision-makers if capacity is lacking. Pre-test probability of incapacity is elevated in populations with known cognitive impairment (e.g., dementia prevalence ~10% in patients >65 years). Post-test probability following an abnormal MacCAT-CR is >90%. Documentation should include date, time, persons present, topics discussed, and patient questions. Audio or video recording may be used per institutional policies (GCP guidelines).","management_principles":"Not applicable as a therapeutic management. However, best practices for consent management include: Standardized consent forms that cover purpose, procedures, risks, benefits, and alternatives; iterative discussions to reinforce comprehension; use of plain language and teach-back techniques; involvement of translators or cultural mediators when language barriers exist; periodic re-consent when new information becomes available (e.g., protocol amendments in research). Institutions should maintain electronic records of consent documents with audit trails per GCP (Good Clinical Practice) and HIPAA regulations. Training programs for clinicians on communication skills have been shown to increase patient comprehension by 30% (Healey et al. Patient Educ Couns, 2016).","follow_up_guidelines":"Informed consent is not a longitudinal treatment but a continuing process in research and clinical care. Follow-up involves: re-assessment of comprehension and voluntariness whenever new risks emerge, when protocols change, or when the patient\u2019s cognitive status changes; documentation of these re-consent events; and ensuring retention of consent records for the duration required by regulatory bodies (e.g., 3 years post-study completion per FDA 21 CFR \u00a711). Quality improvement programs should audit consent processes annually, with metrics such as completeness of documentation (>95% target) and patient comprehension scores (aim >80% correct responses on risk recall quizzes).","clinical_pearls":"1. Informed consent is a process, not a form: Use teach-back to verify understanding (high-yield for boards and practice; Grady NEJM, 2015).\n2. Four elements\u2014disclosure, comprehension, capacity, voluntariness\u2014must all be satisfied (mnemonic: \"DCCV\"); missing any element invalidates consent (Appelbaum NEJM, 2007).\n3. Capacity \u2260 competence: Capacity is assessed clinically and task-specific; legal competence is jurisdiction-dependent (Emanuel JAMA, 2000).\n4. Re-consent is required when new information arises or if the patient\u2019s condition changes; it prevents ethical and regulatory violations (CIOMS, 2016).\n5. Documentation should include patient questions and responses; EHR audit trails serve as legal proof (AMA Opinion 2.1.1).","references":"1. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 8th ed. Oxford University Press; 2019.\n2. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053\n3. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report. 1979.\n4. U.S. Department of Health and Human Services. Federal Policy for the Protection of Human Subjects (\u201cCommon Rule\u201d). 45 C.F.R. Part 46; 2018.\n5. American Medical Association. AMA Code of Medical Ethics Opinion 2.1.1: Informed Consent. 2020.\n6. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA. 2000;283(20):2701-2711. doi:10.1001/jama.283.20.2701\n7. Silverman HJ, Hull SC, Wilfond BS. The ethics of clinical research. Chest. 2011;140(5):1252-1256. doi:10.1378/chest.11-0420\n8. Appelbaum PS. Assessment of patients' capacities to consent to treatment. N Engl J Med. 2007;357(18):1834-1840. doi:10.1056/NEJMcp074045\n9. Grady C. Enduring and emerging challenges of informed consent. N Engl J Med. 2015;372(9):855-862. doi:10.1056/NEJMra1411250\n10. Council for International Organizations of Medical Sciences. International Ethical Guidelines for Health-related Research Involving Humans. CIOMS; 2016.\n11. Council of Europe. Convention on Human Rights and Biomedicine (Oviedo Convention). 1997.\n12. AAP Committee on Bioethics. Informed consent in pediatric practice. Pediatrics. 2016;137(2):e20153683. doi:10.1542/peds.2015-3683\n13. Emanuel EJ, Miller FG. The ethics of placebo-controlled trials\u2014A middle ground. N Engl J Med. 2001;345(12):915-919. doi:10.1056/NEJM200109203451209\n14. European Parliament and Council. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use. 2014.\n15. National Bioethics Advisory Commission. Ethical issues in human stem cell research. 1999."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"}]